AMILI, a Singaporean gut microbiome startup, has raised $10.5 million in Series A funding

AMILI, a Singapore-based precision gut microbiome company, has raised $10.5 million in a Series A funding round led by Vulcan Capital, a technology and life sciences investor.

Pruksa Group, TVM Capital Healthcare, Emtek Group, Capital Code, Pureland Group, Blue7, and Enterprise Singapore's investment arm SEEDS Capital are among the new investors in the round.

The company, which was founded in 2019, is creating a massive....